2024年中国肺移植临床研究年度盘点

Annual review of clinical research on lung transplantation of China in 2024

  • 摘要: 肺移植作为目前公认的唯一有效的治疗终末期肺病的方法,提高了患者生存质量。但目前肺移植仍面临诸多挑战,包括排斥反应、感染、移植后急性肾损伤、移植后糖尿病、缺血-再灌注损伤、供者短缺等。2024年,中国肺移植学者在临床研究领域取得了一系列重要进展,着眼于上述问题的研究和解决,并为肺移植手术提供了新的思路。本文就2024年度肺移植领域的临床研究和技术创新展开系统综述,总结我国2024年度在肺移植领域临床研究取得的成果,以期为未来的研究提供新的方向和策略。

     

    Abstract: Lung transplantation is currently the only recognized effective treatment for end-stage lung disease and has improved the quality of life for patients. However, lung transplantation still faces many challenges, including rejection, infection, post-transplant acute kidney injury, post-transplant diabetes mellitus, ischemia-reperfusion injury and donor shortage, etc. Chinese lung transplantation scholars made a series of important progress in the field of clinical research in 2024, focusing on the study and solution of the above problems, and providing new ideas for lung transplantation surgery. This article systematically reviews the clinical research and technological innovation in the field of lung transplantation in 2024, summarizes the achievements of clinical research in the field of lung transplantation in China in 2024, and aims to providing new directions and strategies for future research.

     

/

返回文章
返回